02126.HK
JW (Cayman) Therapeutics Co. Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 2.22
−0.45%Year over year
Reported trailing growth
- Revenue
- +60.8%
- EBITDA
- +19.5%
- EBIT
- —
- EPS
- +46.3%
- Free cash flow
- +44.8%
- Operating cash flow
- +45.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +23.8%
- EBITDA
- +56.7%
- EBIT
- +47.4%
- Net income
- +8.4%
- EPS
- +9.1%
- Free cash flow
- +77.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026